The effect of haem biosynthesis inhibitors and inducers on intestinal iron absorption and liver haem biosynthetic enzyme activities.
The relation between haem biosynthesis and intestinal iron absorption is not well understood, we therefore investigated the effect of compounds that alter haem metabolism on duodenal iron absorption. CD1 mice were treated with either an inhibitor (succinyl acetone (SA)) or stimulator (2-allyl-2-isopropylacetamide (AIA)) of haem biosynthesis. 5-Aminolaevulinic acid (ALA) dehydratase and urinary ALA and porphobilinogen (PBG) levels, were determined. Intestinal iron absorption was assayed with in vivo and in vitro techniques. Liver hepcidin (Hamp1) and duodenal iron transporter mRNA levels were measured using RT-PCR. AIA caused increased hepatic ALA synthase (1.6-fold) and ALA dehydratase (1.4-fold, both p<0.005) activities and increased urinary ALA and PBG excretion (2.1- and 1.4-fold, p<0.005, p<0.05, respectively). In vivo intestinal iron absorption was reduced to 49% of control (p<0.005). Mice treated with SA showed decreased urinary ALA and PBG levels (75 and 55% control, both p<0.005) and reductions in both ALA synthase and ALA dehydratase activities (77 and 56% control, p<0.05, p<0.005, respectively) in the liver. Liver and duodenal haem and cytochrome oxidase levels were not significantly decreased. Iron absorption was enhanced (1.26-fold, p<0.05) and hepatic Hamp1 mRNA was reduced (53% of control, p<0.05). In vitro duodenal iron uptake after mice were injected with SA also demonstrated an increase in Fe(III) reduction and uptake (1.27- and 1.41-fold, p<0.01 respectively). Simultaneous injections of SA and ALA blocked the enhancing effect on iron absorption seen with SA alone. We conclude that alterations in haem biosynthesis can influence iron absorption and in particular, the intermediate ALA seems to be an inhibitor of iron absorption.
Laftah
A H
AH
Nutrition Sciences Division, King's College London, Franklin Wilkins Building, Stamford Street, London SE1 9NH, UK.
Simpson
R J
RJ
Peters
T J
TJ
Raja
K B
KB
D000502:Allylisopropylacetamide / Q000494:pharmacology; D000622:Aminolevulinic Acid / Q000378:metabolism* / Q000652:urine; D000818:Animals; D023181:Antimicrobial Cationic Peptides / Q000378:metabolism; D004386:Duodenum / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006418:Heme / Q000096:biosynthesis*; D064451:Hepcidins; D006537:Heptanoates / Q000494:pharmacology; D007408:Intestinal Absorption; D058085:Iron Compounds / Q000493:pharmacokinetics*; D008297:Male; D051379:Mice; D011162:Porphobilinogen / Q000378:metabolism; D000623:Porphobilinogen Synthase / Q000378:metabolism; D012333:RNA, Messenger / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction
D023181:Antimicrobial Cationic Peptides; D004791:Enzyme Inhibitors; C579599:Hamp protein, mouse; D064451:Hepcidins; D006537:Heptanoates; D058085:Iron Compounds; D012333:RNA, Messenger; D000502:Allylisopropylacetamide; D006418:Heme; C020804:succinylacetone; D011162:Porphobilinogen; D000622:Aminolevulinic Acid; D000623:Porphobilinogen Synthase